Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2–10-year-old children: results of an open, randomised, controlled study
Open Access
- 11 January 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Pediatrics
- Vol. 172 (5), 601-612
- https://doi.org/10.1007/s00431-012-1924-0
Abstract
In Europe, the introduction of monovalent meningococcal serogroup C (MenC) conjugate vaccines has resulted in a significant decline in MenC invasive disease. However, given the potential for strain evolution and increasing travel to areas of high endemicity, protection against additional serogroups is needed. In this study, the immunogenicity, measured by a serum bactericidal activity assay using rabbit complement (rSBA), and the safety of a quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) were compared to that of a licensed monovalent MenC conjugate vaccine (MenC-CRM197) in children 2–10 years of age. Children were randomised (3:1) to receive a single dose of either MenACWY-TT or MenC-CRM197. Non-inferiority of the immunogenicity of MenACWY-TT versus MenC-CRM197 in terms of rSBA-MenC vaccine response was demonstrated. Exploratory analyses suggested that rSBA-MenC geometric mean titres adjusted for pre-vaccination titres were lower in children vaccinated with MenACWY-TT compared to MenC-CRM197. Nevertheless, at 1 month post-vaccination, ≥99.3 % of the children who received MenACWY-TT had rSBA titres ≥1:128 for each of the four vaccine serogroups, which is the more conservative correlate of protection. The reactogenicity and safety profile of MenACWY-TT was clinically acceptable and no serious adverse events considered related to vaccination were reported throughout the study. Conclusion: When administered to European school-age children, MenACWY-TT has a clinically acceptable safety profile and, when compared with MenC-CRM197, the potential to broaden protection against meningococcal disease caused by serogroups A, W-135 and Y while maintaining protection against MenC. This study has been registered at www.clinicaltrials.gov NCT00674583.Keywords
This publication has 51 references indexed in Scilit:
- Is a single dose of meningococcal serogroup C conjugate vaccine sufficient for protection? experience from the NetherlandsBMC Infectious Diseases, 2012
- Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in AfricansThe New England Journal of Medicine, 2011
- Immunogenicity and Safety of H influenzae Type b–N meningitidis C/Y Conjugate Vaccine in InfantsPEDIATRICS, 2011
- Persistence, Replacement, and Rapid Clonal Expansion of Meningococcal Carriage Isolates in a 2008 University Student CohortJournal of Clinical Microbiology, 2011
- Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal diseaseVaccine, 2009
- Global epidemiology of meningococcal diseaseVaccine, 2009
- Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United KingdomClinical and Vaccine Immunology, 2009
- Impact of Meningococcal Serogroup C Conjugate Vaccines on Carriage and Herd ImmunityThe Journal of Infectious Diseases, 2008
- Validation of Serological Correlate of Protection for Meningococcal C Conjugate Vaccine by Using Efficacy Estimates from Postlicensure Surveillance in EnglandClinical and Vaccine Immunology, 2003
- Standardisation and Validation of Serological Assays for the Evaluation of Immune Responses to Neisseria meningitidis Serogroup A and C VaccinesBiologicals, 2000